Results 61 to 70 of about 1,402,994 (298)

Transcriptional network analysis of PTEN‐protein‐deficient prostate tumors reveals robust stromal reprogramming and signs of senescent paracrine communication

open access: yesMolecular Oncology, EarlyView.
Combining PTEN protein assessment and transcriptomic profiling of prostate tumors, we uncovered a network enriched in senescence and extracellular matrix (ECM) programs associated with PTEN loss and conserved in a mouse model. We show that PTEN‐deficient cells trigger paracrine remodeling of the surrounding stroma and this information could help ...
Ivana Rondon‐Lorefice   +16 more
wiley   +1 more source

Transparency in the secondary use of health data: assessing the status quo of guidance and best practices

open access: yesRoyal Society Open Science
We evaluated what guidance exists in the literature to improve the transparency of studies that make secondary use of health data. To find peer-reviewed papers, we searched PubMed and Google Scholar.
Olmo R. van den Akker   +4 more
doaj   +1 more source

From responsible research to responsible innovation: challenges in implementation

open access: yesEngineering Biology, 2017
This study proposes a new approach to the responsible development of innovative products, processes and services by companies and organisations operating in the bioeconomy and related industry sectors.
Joyce Tait
doaj   +1 more source

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

open access: yesMolecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak   +4 more
wiley   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

open access: yesMolecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat   +8 more
wiley   +1 more source

Investigating Past, Present, and Future Trends on Interface Between Marine and Medical Research and Development: A Bibliometric Review

open access: yesMarine Drugs
The convergence of marine sciences and medical studies has the potential for substantial advances in healthcare. This study uses bibliometric and topic modeling studies to map the progression of research themes from 2000 to 2023, with an emphasis on the ...
Mehdi Zamani   +4 more
doaj   +1 more source

Responsibility and innovation

open access: yesJournal of Responsible Innovation, 2022
Ethics & Philosophy of ...
openaire   +4 more sources

Genetic attenuation of ALDH1A1 increases metastatic potential and aggressiveness in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Aldehyde dehydrogenase 1A1 (ALDH1A1) is a cancer stem cell marker in several malignancies. We established a novel epithelial cell line from rectal adenocarcinoma with unique overexpression of this enzyme. Genetic attenuation of ALDH1A1 led to increased invasive capacity and metastatic potential, the inhibition of proliferation activity, and ultimately ...
Martina Poturnajova   +25 more
wiley   +1 more source

Responsible retrospection: adapting responsible innovation to the liminal innovation of ICTs

open access: yesJournal of Responsible Innovation
ICTs are ubiquitous in today's digitised societies, but Responsible Innovation (RI) approaches are ill-equipped to address the liminal nature of ICT innovation. ICTs remain malleable after their diffusion.
Ivan Veul, Lotte Krabbenborg
doaj   +1 more source

Home - About - Disclaimer - Privacy